Futibatinib in Patients With Specific FGFR Aberrations
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients
with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts:
patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4
rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]);
patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2
amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.